Pontine Glioma

04/01/2012 - "Diffuse intrinsic pontine gliomas (DIPG) can not be cured with current treatment modalities. "
05/01/2014 - "The purpose of this study is to evaluate quantitative changes in diffusion tensor imaging (DTI) tractography and fractional anisotropy (FA) of the pons along with clinical correlation, in patients who receive re-irradiation for progressive diffuse intrinsic pontine glioma (DIPG). "
01/01/2013 - "To study the impact of multiparametric MRI and (18)F-FDG-PET on the outcome of children with diffuse intrinsic pontine gliomas (DIPG). "
11/01/2012 - "Pediatric diffuse intrinsic pontine glioma (DIPG) has a dismal prognosis that has not seen a change in outcome despite multiple clinical trials. "
07/01/2012 - "Despite numerous clinical trials over the past 2 decades, the overall survival for children diagnosed with diffuse intrinsic pontine glioma (DIPG) remains 9-10 months. "

11/01/2014 - "Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma."
04/01/2011 - "Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma."
02/01/2011 - "Nimotuzumab for pediatric diffuse intrinsic pontine gliomas."
06/01/2014 - "Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood."
08/01/2013 - "Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. "

03/01/2014 - "We investigated the efficacy of the Wee1 inhibitor MK-1775 in combination with radiation for the treatment of pediatric high-grade gliomas (HGGs), including diffuse intrinsic pontine gliomas (DIPGs). "

12/01/2014 - "Commentary on: "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma." By Burzynski et al."
12/01/2014 - "Comment to the paper: The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma : Stanislaw R. "
12/01/2014 - "Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al."
12/01/2014 - "Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. "
12/01/2014 - "Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al."

11/01/2014 - "We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response. "
11/01/2014 - "Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy."
04/01/2014 - "Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. "
04/01/2011 - "Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group."
12/01/2013 - "Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04)."

11/01/2010 - "Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma."
06/01/2013 - "Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma."
11/01/2010 - "To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. "
09/01/2013 - "Knee radiographs and magnetic resonance imaging (MRI) were prospectively obtained on patients enrolled on two consecutive clinical trials using vandetanib, a potent oral (VEGF receptor 2) VEGFR-2 inhibitor alone or combined with dasatinib, a multiple tyrosine kinase inhibitor, in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). "

07/01/2015 - "Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma."
06/01/2013 - "Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma."
09/01/2013 - "Knee radiographs and magnetic resonance imaging (MRI) were prospectively obtained on patients enrolled on two consecutive clinical trials using vandetanib, a potent oral (VEGF receptor 2) VEGFR-2 inhibitor alone or combined with dasatinib, a multiple tyrosine kinase inhibitor, in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). "

01/01/2013 - "Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study."
10/01/2008 - "The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. "
10/01/2008 - "Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study."

11/01/2014 - "Recent sequencing studies have shown that ~30 % of pediatric GBM and ~80 % of diffuse intrinsic pontine gliomas show K27M mutations in the H3F3A gene, a variant encoding histone H3.3. H3F3A K27M mutations lead to global reduction in H3K27me3. "
12/01/2015 - "Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes."
09/01/2012 - "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas."
03/01/2012 - "Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas."
06/01/2015 - "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78 % of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36 % of non-brainstem gliomas carrying either K27M or G34R/V mutations. "

10/21/2002 - "Oral trophosphamide in combination with etoposide did not improve survival of pontine glioma patients. "
10/21/2002 - "To evaluate the overall survival of paediatric patients with pontine gliomas treated with oral trophosphamide and etoposide. "
10/21/2002 - "Treatment of paediatric pontine glioma with oral trophosphamide and etoposide."
01/01/1998 - "The use of concurrent carboplatin and etoposide with hyperfractionated radiation therapy did not appear to improve the survival in this group of children with diffuse pontine gliomas. "
01/01/1998 - "Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study."

01/01/2012 - "A 7-year-old boy was treated with radiation and chemotherapy for a diffuse pontine glioma. "
06/01/2011 - "The biology of diffuse intrinsic pontine glioma remains poorly understood and the dismal prognosis has not changed despite various attempts to add chemotherapy to standard radiation. "
05/01/2006 - "Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas."
11/01/1996 - "Twelve months later following chemotherapy and radiotherapy, neurologic examination and neuroradiologic studies disclosed a recurrence of the pontine glioma. "
05/01/1996 - "Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy."

07/01/2014 - "Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma."
09/01/2011 - "Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience."
04/01/2009 - "For patients with diffuse pontine glioma, our institution offers local radiotherapy and supportive care only. "
11/01/2007 - "Diffuse pontine glioma remains a devastating disease despite numerous attempts to improve on the standard radiotherapy. "
01/01/2007 - "We report two cases of diffuse pontine glioma diagnosed clinicoradiologically and treated with conventional radiotherapy. "

12/01/2014 - "A new study reveals that inhibition of JMJD3 has robust antitumor activity in diffuse intrinsic pontine glioma xenografts."
05/01/2012 - "An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing."

09/01/1992 - "Stereotactic implantation of the afterloading catheters using the Brown-Roberts-Wells computed tomography (CT)-guided stereotactic system was performed in 24 patients and surgical implantation in two patients with pontine glioma. "

10/01/2014 - "Superselective intracerebral catheterization for administration of oncolytic virotherapy in a case of diffuse intrinsic pontine glioma."